This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrandomized, multicenter, prospective study conducted at 13 institutions in Japan (jRCTs031190236). The study included Child–Pugh Class A patients with advanced HCC who had received pretreatment with atezolizumab plus bevacizumab (Atez/Bev) or lenvatinib. Ramucirumab was introduced as a second-line treatment after Atez/Bev or lenvatinib and as a third-line treatment after Atez/Bev and lenvatinib. Between May 2020 and July 2022, we enrolled 19 patients, including 17 who received ramucirumab. Additionally, seven patients received lenvatinib, another seven patients received Atez/Bev, and three patients received Atez/Bev followed by lenvatinib as prior treatment. The primary endpoint was a 6-month progression-free survival (PFS) rate, which was 14.3%. The median PFS and overall survival were 3.7 and 12.0 months, respectively. The most common grade ≥ 3 adverse events (AEs) were hypertension (23.5%), proteinuria (17.6%), and neutropenia (11.8%). The discontinuation rate due to AEs was 29.4%. Six patients progressed from Child–Pugh A to B after treatment with ramucirumab. Thirteen patients were eligible for post-ramucirumab treatment, including systemic therapy. Despite the limited number of patients, the efficacy of ramucirumab was comparable to that observed in the REACH-2 study when used after lenvatinib and Atez/Bev. However, the incidence of AEs was higher than that in the REACH-2 study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Hepatocellular carcinoma (HCC), the seventh most common cancer and the third leading cause of cancer-related deaths, is a major global health concern [1]. Its primary origin is the liver, which is often associated with chronic liver diseases stemming from hepatitis B (HBV) and C virus (HCV) infections, alcohol abuse, or metabolic syndrome [2, 3]. HCC is prevalent in Asia, and cases have been increasing worldwide [1‐4]. Despite global guidelines advocating early detection through surveillance of high-risk groups, many patients are still diagnosed at advanced stages [5‐8]. Therefore, addressing the need for enhanced systemic therapies to improve outcomes in advanced HCC is critical.
Since the late 2010s, the treatment of advanced HCC has evolved significantly, starting with lenvatinib, which became the standard of care after the REFLECT trial showed its noninferiority to sorafenib. Further trials have highlighted the improved efficacy of lenvatinib [9]. The IMbrave 150 trial showed that the combination of atezolizumab and bevacizumab (Atez/Bev) outperformed sorafenib in terms of overall survival (OS), making it the preferred first-line treatment for advanced HCC [10]. The real-world efficacy of lenvatinib exceeds the results observed in the REFLECT trial [11, 12]. If immunotherapy is inadequate, lenvatinib is frequently used as a second-line treatment. In practical applications, lenvatinib is often preferred over sorafenib among tyrosine kinase inhibitors.
Anzeige
Ramucirumab, a vascular endothelial growth factor receptor (VEGFR)-2-targeting human immunoglobulin G monoclonal antibody, disrupts the VEGFR-2/vascular endothelial growth factor A (VEGF-A) interaction and reduces endothelial cell proliferation and migration [13‐15]. Although the original REACH study did not show an OS benefit with best supportive care after progression on sorafenib, a subgroup analysis showed a significant benefit in patients with α-fetoprotein (AFP) levels of > 400 ng/mL [16]. This led to the REACH-2 trial, which confirmed the efficacy of ramucirumab in this specific patient population, leading to its approval as a standard second-line treatment for advanced HCC [17]. Because sorafenib is no longer the primary first-line therapy, the use of ramucirumab has adapted and is now typically administered after failure or intolerance to combination immunotherapy, such as Atez/Bev or lenvatinib. This evolving treatment context highlights the need to reevaluate the role of ramucirumab in advanced HCC. Therefore, this prospective study aimed to evaluate the safety and efficacy of ramucirumab in a contemporary real-world clinical setting for advanced HCC.
Materials and methods
Study design and patients
The R-evolution study, a multicenter, non-randomized, single-arm study, was conducted at 13 centers in Japan. Patients aged 20 years and older who were diagnosed with HCC confirmed by histology, cytology, or typical radiologic examination were enrolled. The study included patients who were ineligible for curative resection/local ablation and those ineligible for or unlikely to benefit from transcatheter arterial chemoembolization. Inclusion criteria encompassed a baseline Eastern Cooperative Oncology Group performance status of 0 or 1, Child–Pugh Class A, and measurable target lesions as defined by RECIST version 1.1, as well as a history of ineffective treatment or intolerance of first-line lenvatinib, first-line Atez/Bev, or Atez/Bev followed by lenvatinib. Eligibility also required adequate hematologic and organ function, as confirmed by baseline laboratory tests, including white blood cell count, neutrophil count, hemoglobin, platelet count, total bilirubin, aspartate aminotransferase, alanine aminotransferase, serum creatinine, and coagulation function. Major exclusion criteria were a history of other malignancy within the past 3 years, uncontrolled or significant cardiovascular disease, renal insufficiency requiring dialysis, active bacterial infection, grade ≥ 2 encephalopathy, a portal to main circulation shunt with hepatic encephalopathy, uncontrolled ascites, esophagogastric varices requiring treatment, history of variceal rupture, thromboembolism in the past 6 months, long-term antiplatelet therapy (except daily aspirin), and HBV DNA levels above the detection sensitivity without nucleotide analog treatment.
This study followed the International Conference on Harmonization Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent. The institutional review board or ethics committee at each site approved the study protocol. The Certified Clinical Research Review Board at Chiba University approved the R-evolution trial on January 22, 2020, and approval was obtained from each participating institution (jRCTs031190236).
Procedure
The patients received intravenous ramucirumab at 8 mg/kg every 2 weeks, similar to that in the REACH-2 study. Dose interruptions followed by dose reductions to 6 and 5 mg/kg were allowed for ramucirumab-related toxicities. Safety was assessed from the initiation of ramucirumab administration until study discontinuation. The investigators at each site assessed tumor response using the RECIST version 1.1 criteria. Treatment was continued until disease progression, unacceptable adverse events, patient withdrawal, or discontinuation was deemed in the best interest of the patient by the treating physician. Radiological assessment was performed 4 weeks after ramucirumab administration and then every 8 weeks during treatment. Eventually, treatment could be continued beyond progression if beneficial for the patient.
Anzeige
Outcomes
The primary endpoint of the study was progression-free survival (PFS) at 6 months after ramucirumab initiation. The secondary efficacy endpoints were OS, PFS, and time to progression (TTP). The secondary safety endpoints were the incidence of adverse event (AE)s and discontinuation rate due to AEs. AEs were graded based on the National Cancer Institute Common Terminology Criteria for AEs version 4.0.
Statistical analysis
The sample size was calculated as follows: assuming a 6-month expected PFS of 45% and a threshold PFS of 15%, a sample size of 27 participants would be required to provide 90% power, two-sided α = 5.0%, 12 months of enrollment, and 6 months of follow-up, calculated using the Fleming and Harrington method. We decided to enroll 30 participants to account for an expected dropout rate of 10%. The difference in the safety of ramucirumab between the three groups with each prior treatment will be evaluated as a secondary endpoint. At least one adverse event can be detected in six patients, which was expected to occur in > 30% of patients with a probability of > 75%. Therefore, we required at least six in each of the Atez/Bev, lenvatinib, and Atez/Bev and lenvatinib groups. The Kaplan–Meier was used to estimate the median OS, PFS, and TTP times and their 95% confidence intervals (CIs). All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary, NC, RRID:SCR_008567).
Results
Patient characteristics
We obtained informed consent from 19 patients between March 2020 and June 2022. However, we excluded one patient because of deterioration of liver function prior to the start of treatment. In addition, another patient withdrew consent, thus only the remaining 17 patients received ramucirumab treatment (Supplementary Fig. 1). Table 1 shows the demographic and disease characteristics of the patients. The median age was 73 years, and 14 patients were male. At the initiation of ramucirumab, 6 and 11 patients had a Child–Pugh score of 5 and 6, respectively. Additionally, 14 patients were classified as Barcelona Clinic Liver Cancer stage C at treatment initiation. Median AFP level was 2,366 ng/mL (range, 551–50,270 ng/mL). Regarding prior treatment, 7 patients had received lenvatinib, 7 had received Atez/Bev, and 3 had received Atez/Bev followed by lenvatinib. Supplementary Table 1 shows the demographic and disease characteristics of each group, categorized by prior treatment. Supplementary Fig. 2 shows the changes of AFP levels of each group at the start of prior treatment and ramucirumab administration. All participants discontinued ramucirumab during the study. The median follow-up of the enrolled patients was 6.5 months (range, 2.8–14.4 months). Treatment was discontinued for various reasons during the observation period: 8 patients due to disease progression, 5 patients due to AEs leading to discontinuation, and 4 patients for other reasons, including decisions to withdraw consent.
Table 1
Patient characteristics
Variable
Whole study population
(n= 17)
Age (years, median [range])
73 (42–89)
Sex, male (n [%])
14 (82.4%)
HBV positive (n [%])
8 (47.1%)
HCV positive (n [%])
4 (23.5%)
Alcohol Abuse (n [%])
5 (29.4%)
Child–Pugh score (n [%])
5
6 (35.3%)
6
11 (64.7%)
ECOG-PS, 0 (n [%])
15 (88.2%)
Maximum intrahepatic tumor size ≥ 50 mm (n [%])
9 (52.9%)
Number of tumors, ≥ 8 (n [%])
4 (23.5%)
MVI (n [%])
8 (47.1%)
EHM (n [%])
9 (52.9%)
BCLC-C (n [%])
14 (82.4%)
AFP (ng/mL, median [range])
2,366 (551–50,270)
Prior treatment
Lenvatinib (n [%])
7 (41.2%)
Atez/Bev (n [%])
7 (41.2%)
Atez/Bev followed by lenvatinib (n [%])
3 (17.6%)
Best radiological response of prior treatment
Objective response
3 (17.6%)
Disease control
13 (76.5%)
Cause for the discontinuation of prior treatment, disease progression
13 (76.5%)
HBV hepatitis B virus, HCV hepatitis C virus, ECOG-PS Eastern Cooperative Oncology Group performance status, MVI macrovascular invasion, EHM extrahepatic metastasis, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, Atez/Bev atezolizumab plus bevacizumab
Efficacy
Figure 1 shows the Kaplan–Meier curves for PFS and OS. The 6-month PFS rate after ramucirumab initiation was 14.3% (95% CI, 0.9%–45.0%). The median PFS was 3.7 months (95% CI, 1.2–4.6) (Fig. 1A). The median OS was 12.0 months (95% CI, 4.9 months to not evaluable) (Fig. 1B). Figure 2A shows the swimmer plot visualizations showing the treatment duration and best responses for all patients. None of the study participants achieved a complete or partial response. Twelve patients had stable disease at their first radiological evaluation, whereas the remaining five patients had disease progression. The objective response and disease control rates were 0% and 70.6%, respectively. Notably, six patients remained on ramucirumab for > 2 months, whereas five patients discontinued treatment within the first month of administration. The treatment duration among the three groups classified based on their prior treatment regimens did not show significant differences. Figure 2B shows the best percentage change from baseline in target lesions for each patient. Although one patient had an approximately 40% increase in lesion size, most target lesion changes during treatment were generally within the 20% range. Supplementary Table 2 shows the detailed results of the prognostic analyses and best responses segmented by prior treatment. In the 12 patients where the best response to ramucirumab was disease control, 10 (83.3%) patients had disease control in prior treatments, while 2 (16.7%) patients experienced disease progression. On the other hand, among the 5 patients whose best response to ramucirumab was disease progression, 3 (60.0%) patients achieved disease control in prior treatments, while 2 (40.0%) patients showed disease progression (Supplementary Table 3).
Fig. 1
Survival analyses of patients with advanced hepatocellular carcinoma who received ramucirumab. A Progression-free survival. B Overall survival
Fig. 2
Efficacy of ramucirumab in 17 patients treated for advanced hepatocellular carcinoma. A Swimmer’s plot of treatment duration and the best response. B Best percent change in target lesions. Response was evaluated based on RECIST version 1.1. Abbreviation: SLD, sum of longest diameters
×
×
Safety
In this cohort, all patients experienced AEs of varying severity (Fig. 3 and Supplementary Table 4). Grade ≥ 3 AEs were observed in 12 patients (70.6%), with the most common being hypertension, proteinuria, and neutropenia in 23.5%, 17.6%, and 11.8% of patients. Regarding prior treatment category, the incidence of grade ≥ 3 AEs was highest in patients who received ramucirumab after lenvatinib at 85.7%, followed by 66.7% for patients treated with Atez/Bev followed by lenvatinib, and 57.1% for patients treated with Atez/Bev (Supplementary Table 5). Ramucirumab treatment had to be either interrupted or postponed in 10 patients (58.8%) during the study, dose reduction in 1 patient, postponement in 8 patients, and both dose reduction and postponement in 1 patient. The main causes for dose modification were decreased appetite, proteinuria, limb edema, and weight loss in two patients (11.8%). In addition, 5 patients (29.4%) had to discontinue treatment because of AEs, specifically proteinuria (2 patients), limb edema (1 patient), atrioventricular block (1 patient), and tumor lysis syndrome (1 patient).
Fig. 3
Incidence rates of adverse events in patients with advanced hepatocellular carcinoma receiving ramucirumab. Adverse events occurring ≥ 10% are presented in this figure
×
Transition of liver function and posttreatment after ramucirumab administration
Figure 4A shows the progression of Child–Pugh scores over the course of ramucirumab treatment. Among patients who started with a Child–Pugh score of 5, 66.7% (4 patients) remained in Child–Pugh class A, whereas 33.3% (2 patients) progressed to class B. Similarly, among patients with an initial score of 6, 63.6% (7 patients) remained in Child–Pugh class A, and 36.4% (4 patients) progressed to class B. The Child–Pugh scores of 10 patients did not change after ramucirumab treatment. Three patients had a one-point increase, three had a two-point increase, and one had a one-point decrease. Figure 4B–D shows the changes in albumin bilirubin (ALBI) levels at baseline and the end of ramucirumab treatment in each group classified based on the prior treatment, which indicates a lack of a consistent pattern of response. Supplementary Table 6 shows the options for subsequent anticancer treatments after ramucirumab administration. Most patients in the cohort (76.5%) could progress to subsequent treatments. Specifically, two patients progressed to hepatic arterial infusion chemotherapy, one patient received radiotherapy, and 10 patients received next-line systemic chemotherapy. The rates of progression to subsequent anticancer treatments were 85.7% for those who had previously received lenvatinib, 71.4% for those who had received Atez/Bev, and 66.7% for those who had received Atez/Bev and lenvatinib.
Fig. 4
Transition of liver function reserve during ramucirumab treatment. A Correlation of Child–Pugh score at baseline and at end of ramucirumab treatment. B Transition of ALBI score. Purple line shows patients who received ramucirumab after lenvatinib. C Transition of ALBI score. Blue line shows patients who received ramucirumab after atezolizumab plus bevacizumab. D Transition of ALBI score. Green line shows patients who received ramucirumab after atezolizumab plus bevacizumab followed by lenvatinib. Abbreviation: ALBI, albumin bilirubin
×
Discussion
This prospective study was designed to evaluate the efficacy and safety of ramucirumab, particularly considering the shift in treatment of advanced HCC to the combination of Atez/Bev and lenvatinib. Although we were unable to reach its planned enrollment, it provided valuable data on the use of ramucirumab in the current treatment landscape for advanced HCC.
The primary endpoint of the study, the 6-month PFS rate for ramucirumab, was 14.3%, with a median PFS of 3.7 months, which was generally consistent with the efficacy of ramucirumab in the REACH-2 trial. The swimmer’s plot data showed that only 5 of 17 patients had disease progression at the first radiological evaluation, identifying them as “early progression patients,” indicating that ramucirumab achieved a degree of disease stabilization in a significant proportion of the participants. In actual clinical practice in Japan, ramucirumab will be administered often in the future as a follow-up treatment to either Atez/Bev or lenvatinib, mirroring the approach in this study. Although the combination of Atez/Bev is still awaiting approval, real-world data on ramucirumab in 79 patients who had received at least one or two prior therapies have been reported [18]. In this cohort, most patients had previously been treated with lenvatinib, showing a PFS of 3.2 months for those who received one or more prior treatments. Conversely, a retrospective study examining the effectiveness of ramucirumab after lenvatinib treatment in a small patient group reported a PFS of 2.0 months [19]. A recent retrospective study by Kuzuya et al., investigating the efficacy of ramucirumab following Atez/Bev, reported a TTP of 3.0 months [20]. Our prospective study’s findings align closely with these reports, indicating our results as reasonable and representative of the efficacy of ramucirumab in a real-world clinical setting.
Anzeige
The incidence of AEs during ramucirumab treatment in our study was significantly higher than that in the REACH-2 study. Specifically, we noted hypertension in 58.8% of all grades and 23.5% of grade ≥ 3 in our study compared with 25% of all grades and 13% of grade 3 or higher in REACH-2. In addition, proteinuria was common and a significant contributor to dose reduction or discontinuation of ramucirumab therapy. Although sorafenib, a tyrosine kinase inhibitor with VEGF inhibitory activity, has a relatively mild inhibition compared with other tyrosine kinase inhibitors approved for HCC [21‐23], such as lenvatinib, our patient cohort had previously received bevacizumab, an anti-VEGF antibody, and lenvatinib as first- and second-line therapy. This prolonged and intense inhibition of the VEGF pathway may have increased the frequency or severity of AEs associated with VEGF inhibition. In our study, the high rate of adverse event-related discontinuation of ramucirumab and the treatment history described above may have influenced these results. In addition, the enrollment of only Japanese patients with advanced HCC who were older than those in the REACH-2 study may also be a contributing factor.
In this study, liver function slightly declined during ramucirumab treatment, which was consistent with previous findings [24]. Both Child–Pugh and ALBI scores remained largely unchanged from baseline to the end of therapy. Preservation of liver function for treating advanced HCC is equally important as tumor control in prolonging prognosis [25]. Currently, eight treatment regimens showed efficacy in international phase 3 trials for advanced HCC and are approved in Japan [26‐28]. These regimens were specifically designed for patients with well-preserved liver function and are classified as Child–Pugh A. Thus, the preservation of liver function is a prerequisite for the approval of treatments for advanced HCC. Although several small studies have reported the safety and efficacy of existing treatments in Child–Pugh B patients, these results were not supported by a high level of evidence [11, 29‐32]. To effectively sequence multiple approved agents, Child–Pugh A liver function should be preserved, thereby expanding the range of posttreatment options, whereas decline in liver function severely limits these options [25]. Notably, in our cohort, 13 of 17 patients could transition to some form of posttreatment.
Currently, combination immunotherapy, including Atez/Bev, is highly recommended as first-line treatment for advanced HCC [26‐28]. For patients who are ineligible for this combination immunotherapy, existing VEGF tyrosine kinase inhibitors are generally considered, with preference for lenvatinib as a first-line alternative in real world practice in Japan [33]. However, the standard of care for patients who are either refractory or intolerant to combination immunotherapy remains unclear. In clinical practice, the median PFS with lenvatinib following Atez/Bev was between 2.0 and 6.1 months, indicating a trend toward shorter PFS compared with its use as first-line therapy [11, 34‐37]. Furthermore, some studies, including our study, showed that the efficacy of other treatments, such as sorafenib, regorafenib, cabozantinib, and ramucirumab, after Atez/Bev does not exceed that of lenvatinib [20, 38, 39]. The exact role of ramucirumab in this setting remains to be determined. In addition, the use of ramucirumab in most countries and regions is limited to patients with AFP levels > 400 ng/mL, a criterion based on the REACH-2 study [17], which limits the patient population eligible for this treatment. The difficulty of enrollment in our study and the small size of most real-world clinical reports on this topic underscores this limitation. Unfortunately, our study results did not clarify the optimal positioning of ramucirumab in the latest treatment sequence for advanced HCC. Notably, ramucirumab showed efficacy comparable to that of REACH-2 in the most recent sequential treatment regimen, with preservation of liver function and a high rate of progression to subsequent treatments. As treatment options expand, a subset of patients with advanced HCC may be able to sequence multiple agents. In such scenarios, maintaining ramucirumab as an option for patients with AFP levels ≥ 400 ng/mL is critical to prolong patient survival.
Our study has several limitations that warrant mention. The primary constraint is the small sample size. Although the efficacy demonstrated in this study, which included a limited number of cases, is considered comparable to that of the REACH-2 trial, further validation of the efficacy of ramucirumab in patients with AFP ≥ 400 ng/mL in later-line treatment is necessary. This is particularly important within the current therapeutic framework, where Atez/Bev combination therapy is established as a first-line treatment. To confirm our findings, validation in a larger prospective cohort is essential. Furthermore, this study is limited to patients who have received prior treatment with Atez/Bev and lenvatinib. Patients who received first-line treatment with Atez/Bev followed by the first-generation tyrosine kinase inhibitor sorafenib and subsequently chose ramucirumab were not enrolled. This is due to the fact that in real-world clinical practice in Japan, lenvatinib is overwhelmingly the tyrosine kinase inhibitor of choice for first-line treatment [33]. Moreover, it is currently expected that the combination therapy of durvalumab and tremelimumab, durvalumab monotherapy, as well as regorafenib and cabozantinib, may be used prior to ramucirumab. Given the current diversification of sequential therapies for advanced HCC, prospectively verifying the safety of ramucirumab in all sequence patterns is challenging, which can be considered a limitation of this study. Lastly, the timing of imaging evaluations based on our trial design may have an impact on the efficacy assessment. In this study, the initial imaging evaluation was performed 4 weeks after the start of treatment. Compared to the REACH-2 trial, which conducted the initial evaluation 6 weeks after treatment initiation, there is a possibility of overestimating the efficacy. Our study prioritized the evaluation of the safety and efficacy of ramucirumab in real-world clinical practice in Japan, and therefore, we chose the commonly selected timepoint of 4 weeks after treatment initiation for the initial evaluation. However, this point should be taken into consideration when interpreting the results of this study.
Anzeige
In conclusion, our study supports the use of ramucirumab in advanced HCC, particularly after Atez/Bev or lenvatinib, highlighting its role in preserving liver function and providing additional treatment options for patients with advanced HCC. Further research and real-world data are essential to optimize advanced HCC treatment strategies.
Acknowledgements
This study was funded by Eli Lilly. We express our heartfelt appreciation to the patients who generously participated in the R-evolution study, their families, and the dedicated R-evolution investigators. We would also like to acknowledge the exceptional efforts of Satomi Nakamura, Yuka Iwase, Ryoko Arai, Yukie Sakuma, and Akie Tsuda for their diligent data management. Finally, we extend our thanks to Enago (www.enago.jp) for their meticulous English review.
Declarations
Ethics approval
This study followed the International Conference on Harmonization Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent. The institutional review board or ethics committee at each site approved the study protocol. The Certified Clinical Research Review Board at Chiba University approved the R-evolution trial on January 22, 2020, and approval was obtained from each participating institution (jRCTs031190236).
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Anzeige
Competing interest
Kazufumi Kobayashi received honoraria from Eli Lilly Japan and Chugai. Sadahisa Ogasawara received honoraria from Eli Lilly Japan and Chugai, consulting or advisory fees from Bayer, Eisai, Merck & Co., Inc., Chugai, Eli Lilly Japan, and AstraZeneca, and research grants from Bayer, Chugai, AstraZeneca, Gilead Sciences, Eli Lilly Japan, and Eisai. Kazuyoshi Nakamura received honoraria from Daiichi Sankyo and Yakult. Michihisa Moriguchi received honoraria from Eisai, Bayer, Eli Lilly Japan, AstraZeneca, Chugai, and Takeda, consulting or advisory fees from Eisai, Bayer, Eli Lilly Japan, AstraZeneca, and Chugai. Masafumi Ikeda received honoraria from Abbott Japan, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly Japan, Gilead Sciences, Merck Sharp & Dohme, Sumitomo Dainippon, and Takeda, consulting and advisory fees from AbbVie, AstraZeneca, Bayer, Chugai, Eisai, Eli Lilly Japan, Merck Sharp & Dohme, and Ono, research funding from AstraZeneca, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly Japan, Merck Sharp & Dohme, Ono, Merck Serono, and Novartis. Atsushi Hiraoka received honoraria from Eli Lilly Japan, Chugai, AstraZeneca, Bayer, and Otsuka. Yutaka Yasui received honoraria from Eli Lilly Japan, Eisai, Chugai, and Takeda. Teiji Kuzuya received honoraria from Bayer, Eisai, Eli Lilly Japan, Takeda, AstraZeneca, and Chugai. Hiroaki Kanzaki received honoraria from Takeda and Bayer. Masanori Inoue received honoraria from AbbVie and Eisai. Masato Nakamura received honoraria from Gilead Sciences, AbbVie, Nobelpharma, Otsuka, and Kowa, and research grant from AbbVie. Takayuki Kondo received honoraria from Janssen Pharmaceutical K.K. Kaoru Tsuchiya received honoraria from Bayer, Eisai, Eli Lilly Japan, Chugai, Takeda, and AstraZeneca. Hiroshi Aikata received honoraria from Eisai and Chugai, research grant from Eisai. Naoki Morimoto received honoraria from Eisai, AbbVie, and Chugai, and research grants from Eisai and AbbVie. Masayuki Kurosaki received honoraria from Eisai, Bayer, Eli Lilly Japan, Chugai, Takeda, and AstraZeneca. Yoshito Itoh received honoraria from Eli Lilly Japan, Bayer, Eisai, Merck Sharp & Dohme, Chugai, and AstraZeneca, research grants from Eli Lilly Japan, Bayer, Eisai, Merck Sharp & Dohme, Chugai, and AstraZeneca. Namiki Izumi received honoraria from Chugai, Eisai, AstraZeneca, Takeda, and Eli Lilly Japan. Naoya Kato received honoraria from Chugai, Eli Lilly Japan, AstraZeneca, and Takeda, consulting or advisory fees from Bayer and Eisai, and research grants from Bayer, Chugai, and Eisai. The other authors have no conflicts of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.
Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.
Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.
Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.
